Compare AKBA & BYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKBA | BYND |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United States |
| Employees | 194 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 231.6M |
| IPO Year | 2014 | 2018 |
| Metric | AKBA | BYND |
|---|---|---|
| Price | $0.89 | $8.29 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 3 | 7 |
| Target Price | ★ $4.67 | $0.83 |
| AVG Volume (30 Days) | ★ 6.3M | 1.3M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.94 | 24.69 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $275,496,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.81 | $0.40 |
| 52 Week High | $3.19 | $15.47 |
| Indicator | AKBA | BYND |
|---|---|---|
| Relative Strength Index (RSI) | 40.12 | 39.52 |
| Support Level | $0.85 | $0.65 |
| Resistance Level | $0.98 | $12.52 |
| Average True Range (ATR) | 0.05 | 0.79 |
| MACD | -0.00 | -0.63 |
| Stochastic Oscillator | 1.40 | 3.48 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.